Vir Biotechnology, Inc. (VIR) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2022
Loading P/E history...
VIR Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Vir Biotechnology, Inc. (VIR) trades at a price-to-earnings ratio of -2.9x, with a stock price of $9.27 and trailing twelve-month earnings per share of $-3.00.
The current P/E is 157% below its 5-year average of 5.1x. Over the past five years, VIR's P/E has ranged from a low of 2.3x to a high of 10.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, VIR trades at a 113% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, VIR trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VIR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VIR P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $74B | 17.1 | 2.70 | +8% | |
| $1B | 177.5 | - | -79% | |
| $2B | 14.1 | - | -26% | |
| $339M | 14.3 | - | -60% | |
| $213M | 1.2Lowest | - | +472% | |
| $166B | 19.8 | 0.15Best | +1684%Best | |
| $358B | 85.5 | - | -1% | |
| $277B | 15.4 | 0.73 | +8% | |
| $2B | 6.9 | 0.67 | +817% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
VIR Historical P/E Data (2021–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $25.31 | $3.81 | 6.6x | +29% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $19.28 | $8.49 | 2.3x | -56% |
| FY2022 Q2 | $25.47 | $8.01 | 3.2x | -38% | |
| FY2022 Q1 | $25.72 | $9.05 | 2.8x | -45% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $41.87 | $3.88 | 10.8x | +110% |
Average P/E for displayed period: 5.1x
See VIR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VIR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VIR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVIR — Frequently Asked Questions
Quick answers to the most common questions about buying VIR stock.
Is VIR stock overvalued or undervalued?
VIR trades at -2.9x P/E, below its 5-year average of 5.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does VIR's valuation compare to peers?
Vir Biotechnology, Inc. P/E of -2.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is VIR's PEG ratio?
VIR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2022.